MX2024006960A - Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2. - Google Patents
Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2.Info
- Publication number
- MX2024006960A MX2024006960A MX2024006960A MX2024006960A MX2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A
- Authority
- MX
- Mexico
- Prior art keywords
- fluoropyridin
- butylamino
- hyperglycemia
- diabetes
- tert
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- SASMSPQPEDQJII-JTQLQIEISA-N C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F Chemical compound C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F SASMSPQPEDQJII-JTQLQIEISA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006960A true MX2024006960A (es) | 2024-06-24 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006960A MX2024006960A (es) | 2021-12-09 | 2022-12-09 | Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (https=) |
| EP (1) | EP4444699A1 (https=) |
| JP (1) | JP2024544698A (https=) |
| KR (1) | KR20240116482A (https=) |
| CN (1) | CN118525004A (https=) |
| AU (1) | AU2022405700A1 (https=) |
| CA (1) | CA3241501A1 (https=) |
| GB (1) | GB2613616A (https=) |
| IL (1) | IL313292A (https=) |
| MX (1) | MX2024006960A (https=) |
| WO (1) | WO2023105035A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| WO2020198466A1 (en) * | 2019-03-27 | 2020-10-01 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240116482A (ko) | 2024-07-29 |
| EP4444699A1 (en) | 2024-10-16 |
| AU2022405700A1 (en) | 2024-06-20 |
| JP2024544698A (ja) | 2024-12-03 |
| GB202117828D0 (en) | 2022-01-26 |
| CN118525004A (zh) | 2024-08-20 |
| US20250042856A1 (en) | 2025-02-06 |
| GB2613616A (en) | 2023-06-14 |
| CA3241501A1 (en) | 2023-06-15 |
| WO2023105035A1 (en) | 2023-06-15 |
| IL313292A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006960A (es) | Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2. | |
| NI201200016A (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteína | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20141421A1 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| PE20190912A1 (es) | Compuesto de piridona como inhibidor de c-met | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| CR20220182A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| CU24099B1 (es) | Derivados de sulfonamida para el tratamiento del dolor | |
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| CO6531464A2 (es) | Morfolinotiazoles como moduladores alostéricos positivos alfa 7 | |
| BR112014009717A2 (pt) | "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica" | |
| AR067118A1 (es) | Sales de amina del acido{4,6-bis(dimetilamino)-2(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acetico, composiciones farmaceuticas que las contienen, procesos de preparacion y usos para el tratamiento de procesos alergicos, dermatitis atopica o trastornos inflamatorios. | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| MX376164B (es) | Composiciones y metodos para tratar el insomnio. | |
| CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
| PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
| CO2017006087A2 (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos |